Key Insights

Highlights

Success Rate

80% trial completion

Published Results

29 trials with published results (18%)

Research Maturity

70 completed trials (43% of total)

Clinical Risk Assessment

Based on trial outcomes

High Risk

Score: 59/100

Termination Rate

10.6%

17 terminated out of 161 trials

Success Rate

80.5%

-6.1% vs benchmark

Late-Stage Pipeline

7%

12 trials in Phase 3/4

Results Transparency

41%

29 of 70 completed with results

Key Signals

29 with results80% success17 terminated

Data Visualizations

Phase Distribution

107Total
Not Applicable (38)
P 1 (26)
P 2 (31)
P 3 (12)

Trial Status

Completed70
Recruiting31
Terminated17
Active Not Recruiting16
Unknown16
Not Yet Recruiting9

Trial Success Rate

80.5%

Benchmark: 86.6%

Based on 70 completed trials

Clinical Trials (161)

Showing 20 of 20 trials
NCT07059884Not ApplicableRecruiting

Distance-Based Exercise to Preserve Function and Prevent Disability

NCT05109468Active Not RecruitingPrimary

Assessment of Patients' Quality of Sexual Life After Anal Cancer Treatment

NCT06493019Phase 2RecruitingPrimary

Study of Pembrolizumab, Carboplatin, Paclitaxel, and Radiation for the Treatment of Early-Stage Anal Cancer

NCT07124000Recruiting

DESTINY-PANTUMOUR04

NCT06904365Active Not Recruiting

Ovarian-Sparing Adaptive Radiotherapy in Young Adult Women

NCT07696169Not Yet Recruiting

Disease Evolution and Risk Factors of AIDS-related Prevalent Cancers

NCT05628194Active Not RecruitingPrimary

ASSESSING THE GAY MALE EXPERIENCE WITH ANAL CANCER PREVENTION STRATEGIES

NCT04287868Phase 1Completed

Combination Immunotherapy in Subjects With Advanced HPV Associated Malignancies

NCT02012699Recruiting

Integrated Cancer Repository for Cancer Research

NCT07425054Phase 2RecruitingPrimary

ctHPVDNA Response-Adapted Chemoradiation +/- Retifanlimab Treatment in Locally-Advanced Anal Cancer

NCT07668284Phase 1Not Yet Recruiting

COQ10 and Vitamin E for Off-Target Radiation Toxicity

NCT05639972Phase 1Recruiting

E7 T-cell Receptor (TCR) -T Cell Induction Therapy for Locoregionally Advanced HPV-associated Cancers

NCT04708470Phase 1Active Not Recruiting

A Phase I/II Study of Combination Immunotherapy for Advanced Cancers Including HPV-Associated Malignancies, Small Bowel, and Colon Cancers

NCT02697084CompletedPrimary

Individual Following in Anal Cancer With PET/CT

NCT05686226Phase 2Recruiting

E7 TCR-T Cell Immunotherapy for Human Papillomavirus (HPV) Associated Cancers

NCT06528353Not ApplicableNot Yet Recruiting

Blood Biomarkers Based Screening for HPV-driven OPC

NCT06263088Not ApplicableRecruiting

EQUITY GI: A Prospective Study to Enhance Quality, Inclusivity, and Trial Participation in Black Patients With Gastrointestinal Cancer.

NCT04432597Phase 1Active Not Recruiting

HPV Vaccine PRGN-2009 Alone or in Combination With Anti-PDL1/TGF-Beta Trap (M7824) in Subjects With HPV Associated Cancers

NCT07192055Not ApplicableRecruitingPrimary

Self-sampling to Optimize Anal Lesion Outcomes

NCT07029152Not ApplicableRecruitingPrimary

Screening for Anal Cancer in Men Who Have Sex With Men Using Pre-Exposure Prophylaxis

Scroll to load more

Research Network

Activity Timeline